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Abstract
Review Article 
IntroductIon
Brain tumours (BTs) constitute approximately 88% of 
all central nervous system (CNS) tumours.[1] However, 
the International Classification of Disease for Oncology 
defines meningeal, pituitary gland, pineal gland and nervous 
tumours (NTs) as CNS tumours.[2]
The malignant and benign BTs consist of a group of diverse 
and uncommon diseases with various presentations according 
to location, morphology, molecular biology and clinical 
behaviour.[3] Due to the different location of these tumours, 
the clinical outcome of malignant or benign tumours is 
different and often life-threatening.[3] The current prevalence 
of BTs is not critical; however, their incidence is rapidly rising 
worldwide.[4] These tumours may present with mental changes 
and neurological deficits, and the social burden of these types 
of tumours is as high as other tumours. Thus, it is essential to 
improve the knowledge of the BTs epidemiology to facilitate 
the diagnosis, prevention and even initial treatment of the 
diseases.[5]
Previous reports demonstrated that the incidence of BTs is 
different among countries worldwide. In general, the incidence 
of BTs is higher in the West than the East and higher in 
developed countries than developing countries.[6] In 2012, 
the CNS tumours accounted for approximately 255,000 new 
cases, <30% of all new cancers worldwide.[7] The age-adjusted 
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distribution of these diseases is also different worldwide, with 
the highest incidence in Australia, North America and North 
Europe and the lowest incidence in Africa. The incidence is 
far more among the Caucasians than African Americans.[8]
Epidemiologic studies in different regions of the world 
indicate that men are more likely at higher risk for BTs 
than women.[9] In addition, an age distribution model also 
indicates that the highest incidence of these cancers occurs in 
adults over 60 years old, adolescents and also children aged 
0–4 years.[10,11]
In Iran, there are a few epidemiological studies about the 
CNS tumours,[12,13] and there is no report of estimate about 
the incidence of these cancers. Since prevention, diagnosis 
and treatment planning need to know about the incidence and 
trend of BTs. No systematic review of the epidemiology of 
CNS cancers carried out in Iran and the present study aimed 
to determine the age-standardised rate (ASR) of brain and 
CNS cancers in Iran.
Methods
The systematic review and meta-analysis were designed and 
conducted based on the preferred reporting items for systematic 
reviews and meta-analyses checklist in 2018.[14]
Search strategy of systematic reviews
A comprehensive search was conducted on all published studies 
of BTs incidence using Medline/PubMed, Scopus, Embase, 
Google Scholar and Web of Sciences as international databases 
and Scientific Information Database (www.sid.ir), MagIran 
(www.magiran.com), IranMedex (vwww.barakatkns.com) and 
IranDoc (www.irandoc.ac.ir), as Iranian national databases 
until April 2018.
The medical subject headings keywords included ‘brain 
tumors’, ‘brain cancers’, ‘brain neoplasms’, ‘central nervous 
system tumours’, ‘nervous system tumours’, ‘epidemiology’, 
‘incidence’ and ‘Iran’. All obtained papers from primary 
searches were imported into an EndNote X7 (Thomson 
Reuters, Carlsbad, CA, USA) library and the duplicates were 
then removed. No time or language limitations were applied.
Inclusion and exclusion criteria
All studies with reports about ASR of BTs among Iranian 
populations were included in the present study. In addition, 
studies with results of prevalence rate, studies with inadequate 
and unreliable sample size and research articles (abstracts, 
poster, letters, comments and editorial papers) were excluded 
from the study.
Quality assessment
The quality of the studies was assessed using the Joanna Briggs 
Institute appraisal.[15] The main objective of this checklist is 
to evaluate the methodological quality and the possibility of 
bias in the design, conduct and analysis of studies. The quality 
assessment results were presented in Table 1.
Risk of bias across studies
Random-effect model was used to minimise the risk of 
bias.[16,17]
Statistical analysis
All analyses were performed using STATA version 12.0 software 
(Stata Corp LP, College Station, TX, USA). Cochran’s Q-test 
(significance level, P ≤ 0.1) complemented with I2 statistic 
(significance, >50%) was used to evaluated heterogeneity of 
results of included studies. The meta-analysis was conducted 
with a random-effect model (with inverse variance method) in 
the studies with significant heterogeneity (P ≤ 0.1 and I2 ≥ 50%).
Table 1: Joanna Briggs Institute critical appraisal checklist applied for included studies in the systematic review
Author name, years Q. 1 Q. 2 Q. 3 Q. 4 Q. 5 Q. 6 Q. 7 Q. 8 Q. 9
Sadjadi, 2003 Yes Yes Yes Yes Yes Yes Yes No Yes
Babaei, 2005 No Yes Yes Unclear Yes Yes Yes Yes No
Esmaeilnasab, 2007 Yes Yes Yes Yes Yes No Yes No Unclear
Sadjadi, 2007 Yes Yes Yes Yes Yes Yes Yes Yes No
Mehrabani, 2008 Yes No No Unclear Yes Yes No Yes Yes
Somi, 2008 Yes Yes Yes Unclear Yes Yes No No Yes
Babaei, 2009 Yes Yes Yes Yes Unclear Yes Yes Yes Yes
Mohagheghi, 2009 Yes Yes Yes Yes Yes Yes Yes Yes Unclear
Mousavi, 2009 Yes Yes Yes Yes Yes Yes No Yes No
Somi, 2009 Yes Yes Yes Yes Unclear Yes No No No
Masoompour, 2011 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Roshandel, 2012 No Yes Yes Yes Unclear Yes Yes Yes Yes
Fateh, 2013 Yes Yes Yes Yes Yes Yes Yes Yes Unclear
Roshandel, 2014 No Yes Yes Yes Unclear Yes Yes Yes Yes
Almasi, 2016 Yes Yes Yes Unclear Yes Yes No No Yes
Amori, 2016 No Yes Yes Yes Yes Yes No No Unclear
Masoompour, 2016 Yes Yes Yes Yes Yes Yes Yes No Yes
Q. 1: Samples were representative?, Q. 2: Participants were appropriately recruited?, Q. 3: Sample size was adequate?, Q. 4: Study subjects and the setting 
were described?, Q. 5: Data analysis was conducted?, Q. 6: Objective, standard criteria and reliably were used?, Q. 7: Appropriate statistical analyses were 
used?, Q. 8: Confounding factors, subgroups and differences were identified and accounted?, Q. 9: Subpopulations were identified using objective criteria?
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results
Description of literature search
The primary searches of databases and also references 
searching of obtained studies yielded 312 potentially eligible 
studies. In total, 95 studies were selected to evaluate more 
accurately, and the review finally included 17 unique studies. 
Duplicate (n = 7) and irrelevant studies (n = 182), studies 
with incorrect study population (n = 11) and inadequate data 
(n = 8) were excluded from the study. The flowchart of the 
studies retrieval and selection in this review has been shown 
in Figure 1.
Description of the included studies
The included studies were published from 2003 to 2016. Based 
on geographical locations, four studies were conducted in all 
states of Iran,[18-21] three in Fars province,[22-24] two in Ardabil 
province,[25,26] two in East Azerbaijan province,[27,28] one in 
Kerman province,[29] one in Kurdistan province,[30] one in 
Golestan province,[31] one in Semnan province,[32] one in Tehran 
metropolis[33] and one in Shahroud city.[34] All the studies have 
reported ASR of BTs. The main characteristics of the selected 
studies have been represented in Table 2.
The results of individual studies
The highest ASR was reported from East Azerbaijan 
province between 2006 and 2007 (9.39 for men and 8.06 for 
women/100,000).[28] On the other hand, the lowest ASR was 
reported from Kurdistan Province in 2003 (0.5 for men and 
0.8 for women/100,000).[30]
The results of meta‑analysis
The results of the random-effect model were demonstrated the 
ASR of BTs was 4.16 (95% confidence interval [CI], 3.20–5.12) 
among men and 3.40 (95% CI, 2.67–4.13) among women. 
Furthermore, the heterogeneity of the studies was confirmed 
by the results of Cochran’s Q-test (Q = 2879.8, df = 18, 
I2 = 98.4%, P < 0.001) for men and (Q = 1864.2, df = 18, 
I2 = 99%, P < 0.001) for women. The forest plots of the 
random-effect meta-analysis for ASR of BTs among Iranian 
population have been represented in Figures 2 and 3 for men 
and women, respectively.
Figure 1: Flowchart of the included studies in the systematic review.
Table 2: Basic characteristics of included studies in the systematic review
Order Author, years Time period Location Sample size ASR (males) ASR (females)
1 Sadjadi, 2003 1996-1999 Ardabil 3455 4.4 3.2
2 Babaei, 2005 1996-2000 Semnan 1732 7 6.26
3 Esmaeilnasab, 2007 2002
2003
Kurdistan 1294 1.3
0.5
2.5
0.8
4 Sadjadi, 2007 1996-2000 Kerman 5884 3.6 3.3
5 Mehrabani, 2008 1990-2005 Fars 2993 2.8 1.46
6 Somi, 2008 2006-2007 East Azerbaijan 4922 4.98 3.68
7 Babaei, 2009 2004-2006 Ardabil 4300 7 6.9
8 Mohagheghi, 2009 1998-2001 Tehran 34,318 6 4.5
9 Mousavi, 2009 2003-2004 Iran 43,014 1.88 1.26
2004-2005 Iran 51,518 2.37 1.64
2005-2006 Iran 61,031 2.51 1.71
10 Somi, 2009 2006-2007 East Azerbaijan 4922 9.39 8.06
11 Masoompour, 2011 1998-2002 Fars 8359 3 2.2
12 Roshandel, 2012 2004-2008 Golestan 9724 7.2 5.3
13 Fateh, 2013 2000-2010 Shahroud 2240 3.65 2.79
14 Roshsndel, 2014 2012 Iran - 4.6 3.8
15 Almasi, 2016 2012 Iran 84,829 - -
16 Amori, 2016 2004-2008 Iran 301,055 2.71 2.32
17 Masoompour, 2016 2007-2010 Fars - 4.44 3.26
ASR: Age-standardised rate
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Figure 2: Forest plot of the random‑effect meta‑analysis for age‑standardised rates of brain tumours among Iranian men.
Advances in Human Biology ¦ Volume 9 ¦ Issue 1 ¦ January-April 2019 5
Publication bias
Egger’s test[35] used to evaluated publication bias. Results of 
Egger’s test showed lack of publication bias (P = 0.185 for 
men and P = 0.227 for women).
dIscussIon
Cancer is the third leading cause of death in Iran.[36] There are 
a few studies on the epidemiology of cancer among population 
of developing countries including Iran.[37-42]
Results of the present study indicated that the ASR of BTs 
was lower in Iranian men and women than those of other 
countries (4.16 and 3.4/100,000 men and women, respectively). 
Based on the previous reports, the incidence of these cancers 
is higher in developed countries such as the United States, 
Canada, England and Australia, than in developing countries.[43] 
Jazayeri et al. have demonstrated in a similar study that the 
standardised incidence of primary CNS tumours in Iran is 
5.69/100,000. This study was limited to obtained data from 
the cancer registry during 2001–2008 and did not cover other 
newer studies.[12] The possible causes of BTs among the 
Iranian population may be associated with the socioeconomic 
level, present risk factors and absence of advanced diagnostic 
methods for BTs in Iran.
There is a huge difference in the incidence of BTs worldwide.[44] 
European countries and Eastern European region including 
Albania, Macedonia, Serbia and Croatia had a high incidence, 
while other countries such as Cyprus, Belarus, Russia and 
Moldova had a low incidence of BTs.[45]
According to the results of conducted studies on refugees, the 
incidence of BTs among migrants to more advanced areas 
was higher than that of native people, indicating the effects of 
environmental factors on CNS malignancy.[46] Global studies 
show an increasing trend for these cancers probably due to the 
aging of those communities.[47,48] The reasons of this increasing 
trend have not been completely determined yet, but one of the 
possible assumptions is the advancement of technology and more 
modern diagnostic methods and tools of these types of cancer.
The present study showed that the highest ASR of BTs among 
people belonged to East Azerbaijan Province and Tabriz city 
(9.39/100,000 for men and 8.68/100,000 for women). The high 
incidence of BTs in this region may be attributed to the specific 
cultural and economic factors, occupational, nutritional and 
environmental exposure, genetic factors and access to better 
diagnostic facilities such as the computed tomography scan, 
magnetic resonance imaging and neurosurgical technologies.[49] 
In other global studies, the ASR was also slightly higher in 
men than women. Regarding race, the incidence of nervous 
system cancers is the highest among American white men and 
the lowest among American black women.[50,51]
Results of the present study indicated that the lowest 
ASR of BTs among Iranian people belonged to Kurdistan 
province (0.5/100,000 for men and 0.8/100,000 for women). 
It is probably due to the incidence of other diseases, cultural 
issues, low levels of risk factors and the lack of advanced 
diagnostic systems in Kurdistan compared to other regions 
of Iran.[30] Environmental factors, including exposure to 
radiation, special dietary factors such as consumption of fruits 
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Figure 3: Forest plot of the random‑effect meta‑analysis for age‑standardised rates of brain tumours among Iranian women.
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